Drugs / KBA1412
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05501821 | Aug 2022 → Jul 2024 | — | Kling Biotherapeutics B.V. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBA1412 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05501821 ↗ |
| Modality | Monoclonal antibody | “fully human, monoclonal antibody” NCT05501821 ↗ |
| Route | Intravenous | “KBA1412 monotherapy, given intravenously, Q3W” NCT05501821 ↗ |
| Target | CD9 | “targeting CD9” NCT05501821 ↗ |